Analysts Set Aligos Therapeutics, Inc. (NASDAQ:ALGS) Price Target at $38.50

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $38.50.

ALGS has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, May 17th. Finally, Lake Street Capital began coverage on shares of Aligos Therapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $45.00 target price for the company.

Aligos Therapeutics Trading Up 3.3%

Shares of ALGS opened at $4.75 on Wednesday. The firm has a market cap of $29.40 million, a PE ratio of -0.55 and a beta of 2.31. Aligos Therapeutics has a 1-year low of $3.98 and a 1-year high of $13.69. The firm has a fifty day simple moving average of $5.35 and a two-hundred day simple moving average of $6.47.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. As a group, research analysts forecast that Aligos Therapeutics will post -7.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Aligos Therapeutics

Hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. increased its stake in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after purchasing an additional 9,000 shares in the last quarter. Susquehanna International Group LLP purchased a new position in Aligos Therapeutics during the third quarter valued at $99,000. XTX Topco Ltd purchased a new position in Aligos Therapeutics during the second quarter valued at $100,000. HRT Financial LP bought a new stake in Aligos Therapeutics during the fourth quarter valued at about $106,000. Finally, DRW Securities LLC bought a new stake in Aligos Therapeutics during the fourth quarter valued at about $111,000. Institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.